HALO Halozyme Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HALO

Price (delayed)

$82.27

Market cap

$9.76B

P/E Ratio

27.79

Dividend/share

N/A

EPS

$2.96

Enterprise value

$11.59B

?
Relative Growth: Rel. Growth: 95
Relative Strength: Rel. Strength: 75
Relative Valuation: Rel. Valuation: 33
Relative Profitability: Rel. Profitability: 92

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE ® drug delivery technology with the ...

Highlights
The company's revenue rose by 39% YoY and by 8% QoQ
HALO's gross profit is up by 38% YoY and by 7% QoQ
HALO's net income is down by 28% year-on-year but it is up by 10% since the previous quarter
HALO's EPS is down by 23% year-on-year but it is up by 12% since the previous quarter
Halozyme Therapeutics's quick ratio has plunged by 69% YoY and by 35% from the previous quarter
The company's equity has shrunk by 54% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.halozyme.com
Peers: MNKD LLY BAX PFE

Key stats

What are the main financial stats of HALO

HALO stock price

How has the Halozyme Therapeutics stock price performed over time
Intraday
-0.33%
1 week
0.97%
1 month
3.55%
1 year
39.39%
YTD
22.24%
QTD
5.11%

Financial performance

How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$1.51B
Gross profit
$1.25B
Operating income
$511.99M
Net income
$348.84M
Gross margin
82.8%
Net margin
23.1%
The net margin has contracted by 48% YoY
The company's revenue rose by 39% YoY and by 8% QoQ
HALO's gross profit is up by 38% YoY and by 7% QoQ
The operating margin has declined by 38% year-on-year

Price vs fundamentals

How does HALO's price correlate with its fundamentals

Growth

What is Halozyme Therapeutics's growth rate over time

Valuation

What is Halozyme Therapeutics stock price valuation
HALO P/E details
P/E
27.79
P/B
44.21
P/S
6.44
EV/EBIT
22.18
EV/EBITDA
18.58
EV/Sales
7.68
The stock's price to earnings (P/E) is 50% more than its last 4 quarters average of 18.5 and 43% more than its 5-year quarterly average of 19.4
HALO's EPS is down by 23% year-on-year but it is up by 12% since the previous quarter
The company's equity has shrunk by 54% YoY
HALO's price to book (P/B) is 24% lower than its last 4 quarters average of 58.3 but 18% higher than its 5-year quarterly average of 37.6
The company's revenue rose by 39% YoY and by 8% QoQ
The price to sales (P/S) is 20% lower than the 5-year quarterly average of 8.1 but 11% higher than the last 4 quarters average of 5.8

Efficiency

How efficient is Halozyme Therapeutics business performance
HALO's return on sales is down by 40% year-on-year
Halozyme Therapeutics's return on assets has decreased by 37% YoY but it has increased by 4.3% QoQ
The ROE has grown by 36% from the previous quarter and by 3.4% YoY
HALO's return on invested capital is down by 14% year-on-year but it is up by 7% since the previous quarter

Dividends

What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HALO.

Financial health

How did Halozyme Therapeutics financials performed over time
The company's total assets is 9% higher than its total liabilities
Halozyme Therapeutics's quick ratio has plunged by 69% YoY and by 35% from the previous quarter
The company's current ratio has shrunk by 67% YoY and by 41% QoQ
Halozyme Therapeutics's debt to equity has plunged by 78% from the previous quarter
The company's equity has shrunk by 54% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.